Data coverage, completeness and provenance for GENETIC TECHNOLOGIES LIMITED in the Stock Market API — Health Care · Diagnostics & Research.
Source date: 2024-10-16T02:07:58. Source: yfinance. Collection time is shown separately and does not establish a trade date.
| Date | Close | Currency | Source | Adjustment basis |
|---|---|---|---|---|
| 2026-10-22 | 0.0390 | AUD | yfinance | Split- and dividend-adjusted close |
| 2026-10-21 | 0.0390 | AUD | yfinance | Split- and dividend-adjusted close |
| 2026-10-20 | 0.0390 | AUD | yfinance | Split- and dividend-adjusted close |
| 2026-10-19 | 0.0390 | AUD | yfinance | Split- and dividend-adjusted close |
| 2026-10-16 | 0.0390 | AUD | yfinance | Split- and dividend-adjusted close |
GET /api/v1/companies/GTG/prices · Price parameters and adjustment semantics
Genetic Technologies Limited, a molecular diagnostics company, engages in the provision of predictive genetic testing and risk assessment tools to help physicians manage people's health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company operates through EasyDNA, AffinityDNA, and GeneType/Corporate segments. It offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. The company also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, it offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include colorectal cancer, ovarian cancer, prostate cancer, coronary artery, type 2 diabetes, pancreatic cancer, melanoma, and atrial fibrillation. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. It has research and collaboration agreements with the University of Melbourne for the development and commercialization of a novel colorectal cancer risk assessment test; Memorial Sloan Kettering Cancer Center of New York and University of Cambridge, that assess the conflict among BRCA mutation carriers considering preventive surgery; and research collaboration with Harvard University, Ohio State University, and Washington University. The company was incorporated in 1987 and is headquartered in Maroochydore, Australia.
Website: https://genetype.com · Profile fields populated: 60%
Share of stored fields populated in the anchor reporting period (FY2025), primary source yfinance. Full per-field breakdown: GET /api/v1/companies/GTG/financials.
Stored values for the most recent fiscal-year periods, with per-period field counts and the primary source each period came from. Values are shown at reported scale without interpretation.
| Period | Period end | Revenue | Net income | Total assets | Total equity | Fields populated | Source |
|---|---|---|---|---|---|---|---|
| FY2025 (AUD) | 2025-06-30 | 30 | yfinance | ||||
| FY2024 (AUD) | 2024-06-30 | 33 | yfinance | ||||
| FY2023 (AUD) | 2023-06-30 | 33 | yfinance | ||||
| FY2022 (AUD) | 2022-06-30 | 33 | yfinance |
The endpoints below describe available datasets for this listing. Missing fields remain unknown. Free API keys — no card required.
Name, sector, industry, HQ, employees, market cap, source-tagged.
GET /api/v1/companies/GTG
Multi-year statements with per-field source tags and completeness.
GET /api/v1/companies/GTG/financials
P/E, P/B, ROE, ROA, margins, EPS, debt/equity — formulas documented.
GET /api/v1/companies/GTG/metrics/summary
Report PDFs with LLM-ready markdown conversions where available.
GET /api/v1/companies/GTG/filings
Dated press releases and announcements with source links.
GET /api/v1/companies/GTG/news
Create a free key, then:
curl -H "X-API-Key: KEY" https://stockmarketapi.ai/api/v1/companies/GTG
Free tier — instant API key. Built for AI agents.